Read more here:
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS®...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh